Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital*

References

• Bertino JS Jr. Integrating fluoroquinolones into the hospital formulary. Pharmacotherapy 2001;21:273S–83S
   Google Scholar
• Schachtner JM, Guharoy R, Medicis JJ, Newman N, Speizer R. Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health-Syst Pharm 2002;59:529–33
   Google Scholar
• Walker SE, Martin WR, Franke TR. Costs and bacterial susceptibility after therapeutic interchange of fluoroquinolones. Am J Health-Syst Pharm 2000;57:1711–2
   Google Scholar
• Halley HJ. Approaches to drug therapy, formulary, and pathway management in a large community hospital. Am J Health-Syst Pharm 2000;57:S17–S21
   Google Scholar
• Clark LC, Davis CW. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Am J Health-Syst Pharm 2000;57:S10–S13
   PubMed Web of Science ®Google Scholar
• Glemaud I. Use of a physician order entry system to identify opportunities for intravenous to oral levofloxacin conversion. Am J Health-Syst Pharm 2000;57:S14–S16
   Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, File TM Jr., Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347–82
   PubMed Web of Science ®Google Scholar
• Cunha BA. Quinolones: clinical use and formulary considerations. Adv Ther 1998;15:277–87
   PubMed Web of Science ®Google Scholar
• Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002;34:1047–54
   PubMed Web of Science ®Google Scholar
• Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 2001;48:375–81
   PubMed Web of Science ®Google Scholar
• Evans ME. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin. Eur J Clin Microbiol Infect Dis 2001;20:883–5
   PubMed Web of Science ®Google Scholar
• Rapp RP, Ribes JA, Overman SB, Darkow TE, Evans ME. A decade of antimicrobial susceptibilities at the university of kentucky hospital. Ann Pharmacother 2002;36:596–604
   Google Scholar
• Zhanel GG, Ennis K, Vercaigne LJ, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002;62:13–59
   PubMed Web of Science ®Google Scholar
• Drusano G, Labro M-T, Cars OF, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infection 1998;4\(Suppl. 2):2S27–41
   Google Scholar
• Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600–3
   Google Scholar
• Zhanel GG, Noreddin AM. Pharmacokinetics and pharmaco-dynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001;1:459–63
   PubMedGoogle Scholar
• Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21:253S–72S
   Google Scholar
• Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593–6
   PubMed Web of Science ®Google Scholar
• Owens RC, Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmaco-therapy 2001;21:301–19
   Google Scholar
• Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468–72
   PubMed Web of Science ®Google Scholar
• Owens RC Jr., Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002;22:663–8
   PubMed Web of Science ®Google Scholar
• Bertino JS Jr., Owens RC Jr., Carnes TD, Iannini PB. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002;34:861–3
   PubMed Web of Science ®Google Scholar
• Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med 2002;113:45S–54S
   Google Scholar
• Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc 2002;287:2215–20
   PubMed Web of Science ®Google Scholar
• Paladino JA. Pharmacoeconomics of antimicrobial therapy. Am J Health-Syst Pharm 1999;56:S25–S28
   Google Scholar
• Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Pharmacotherapy 2001;21:89S–94S
   Google Scholar
• Palmer CS, Zhan C, Elixhauser A, Halpern MT, Rance L, Feagan BG, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000;22:250–64
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Nguyen K-H, Razeghi J. Implementing a program for switching from i.v. to oral antimicrobial therapy. Am J Health Syst Pharm 2001;58:1146–9
   Google Scholar
• Sullivan JG, McElroy AD, Honsinger RW, et al. A double-blind, randomized study of safety and efficacy: treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999;20:S49–S59
   Google Scholar
• Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother 2001;45:2358–62
   PubMed Web of Science ®Google Scholar
• Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003;62:537–41
   PubMed Web of Science ®Google Scholar
• Richard GA, Klimberg IN, Fowler CL, Callery-D’Amico S, Kim SS. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998;52:51–5
   Google Scholar
• Richard GA, Childs SJ, Fowler CL, Safety and efficacy of levofloxacin versus ciprofloxacin in complicated urinary tract infections in adults. Pharm Ther 1998;23:534–40
   Google Scholar
• Beringer PM, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. Pharmacoeconomics 1998;13:35–49
   PubMed Web of Science ®Google Scholar